11-003 report 1 |
Previous | 1 of 4 | Next |
|
small (250x250 max)
medium (500x500 max)
large ( > 500x500)
Full Resolution
All (PDF)
|
This page
All
|
INTERIM STUDY REPORT
Public Health Committee
Rep. John Enns, Chairman
Oklahoma House of Representatives
Interim Study 11-03, Rep. Colby Schwartz
Sept. 27, 2011
Electronic prescribing (eRx)
Drew Duncan, director of government relations
Pfizer
• Any electronic prescribing (eRx) system should improve patient care and strengthen the
physician/patient relationship. It needs to put the patient first.
• It should provide instant information when its needed, where technology and healthcare
interact, intersect.
• Any system should reduce the overall cost of healthcare.
• Pfizer spends $6-8 billion a year on research and development with the goal of creating
new meds everyone can benefit from. Often, there are more misses than hits.
• A primary concern of Pfizer’s is the transparency of all meds. All meds should be
accessible to the physician based on personal judgment of what is best for patient.
• Another concern when looking at eRx is that patients who successfully navigate the prior
authorization process after being written a prescription should be grandfathered into any
new system and not have to go back through the process again, even if they switch
providers.
• Other states, such as FL, KS, ND and ME, have addressed eRx in varying degrees.
John Crumly, executive vice president
Pharmacy Providers of OK
Speaking on behalf of Oklahoma Pharmacists Association
jcrumly@ppok.com
• Since pharmaceutical manufacturers compete as preferred or nonpreferred on a
formulary, there originally was concern that eRx would be used as a tool to influence
physicians.
• There also is concern that it could be used to steer prescriptions to particular providers.
• Most prior authorization tools are web portal or faxed-based and not focused on e-prior
authorizations.
• Ninety percent of pharmacies in Oklahoma are prepared to do eRx now. There are 800
pharmacies in the state, so 700 should be ready.
• The 10 percent that are not ready are primarily in rural areas where some pharmacies
haven’t gotten latest software. However, some grant money is available that could help
Oklahoma get to 100 percent.
• There has been recent exponential growth in eRx. Surescripts is the conduit. In 2009,
they reported over 2 million scripts done via eRx in Oklahoma.
• In 2009, physicians in Oklahoma participated at an 18 percent rate, but that number has
likely risen dramatically because of recent CMS incentives for using technology.
• The Oklahoma doctors that are using eRx are using it a lot because the 2 million scripts
came from only the 18 percent participating.
Object Description
Description
| Title | 11-003 report 1 |
| Full text | INTERIM STUDY REPORT Public Health Committee Rep. John Enns, Chairman Oklahoma House of Representatives Interim Study 11-03, Rep. Colby Schwartz Sept. 27, 2011 Electronic prescribing (eRx) Drew Duncan, director of government relations Pfizer • Any electronic prescribing (eRx) system should improve patient care and strengthen the physician/patient relationship. It needs to put the patient first. • It should provide instant information when its needed, where technology and healthcare interact, intersect. • Any system should reduce the overall cost of healthcare. • Pfizer spends $6-8 billion a year on research and development with the goal of creating new meds everyone can benefit from. Often, there are more misses than hits. • A primary concern of Pfizer’s is the transparency of all meds. All meds should be accessible to the physician based on personal judgment of what is best for patient. • Another concern when looking at eRx is that patients who successfully navigate the prior authorization process after being written a prescription should be grandfathered into any new system and not have to go back through the process again, even if they switch providers. • Other states, such as FL, KS, ND and ME, have addressed eRx in varying degrees. John Crumly, executive vice president Pharmacy Providers of OK Speaking on behalf of Oklahoma Pharmacists Association jcrumly@ppok.com • Since pharmaceutical manufacturers compete as preferred or nonpreferred on a formulary, there originally was concern that eRx would be used as a tool to influence physicians. • There also is concern that it could be used to steer prescriptions to particular providers. • Most prior authorization tools are web portal or faxed-based and not focused on e-prior authorizations. • Ninety percent of pharmacies in Oklahoma are prepared to do eRx now. There are 800 pharmacies in the state, so 700 should be ready. • The 10 percent that are not ready are primarily in rural areas where some pharmacies haven’t gotten latest software. However, some grant money is available that could help Oklahoma get to 100 percent. • There has been recent exponential growth in eRx. Surescripts is the conduit. In 2009, they reported over 2 million scripts done via eRx in Oklahoma. • In 2009, physicians in Oklahoma participated at an 18 percent rate, but that number has likely risen dramatically because of recent CMS incentives for using technology. • The Oklahoma doctors that are using eRx are using it a lot because the 2 million scripts came from only the 18 percent participating. |
| Date created | 2012-03-01 |
| Date modified | 2012-03-01 |
